Edition:
United States

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

12.30EUR
18 Aug 2017
Change (% chg)

€0.12 (+0.94%)
Prev Close
€12.19
Open
€12.10
Day's High
€12.35
Day's Low
€11.84
Volume
396,837
Avg. Vol
101,282
52-wk High
€13.20
52-wk Low
€8.21

ABLX.BR

Chart for ABLX.BR

About

Ablynx NV is a Belgium-based biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx NV has more than 30 proprietary and... (more)

Overall

Beta: 1.59
Market Cap(Mil.): €752.39
Shares Outstanding(Mil.): 61.17
Dividend: --
Yield (%): --

Financials

  ABLX.BR Industry Sector
P/E (TTM): 1,230.00 78.89 32.56
EPS (TTM): 0.01 -- --
ROI: -0.59 2.83 14.89
ROE: -1.66 5.09 16.13

BRIEF-Ablynx announces warrant exercise

* AS A RESULT OF THIS TRANSACTION, ABLYNX NOW HAS 61,169,732 SHARES OUTSTANDING

Aug 11 2017

BRIEF-Ablynx receives FDA fast track designation for Caplacizumab

* ABLYNX RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP

Jul 26 2017

BRIEF-Ablynx issues additional 19,833 common shares

* ADDITIONAL 19,833 COMMON SHARES HAVE BEEN ISSUED BY COMPANY IN EXCHANGE FOR EUR 121,444 AS RESULT OF EXERCISE OF WARRANTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 24 2017

Ablynx signs Sanofi deal potentially worth up to $2.8 billion

French drugmaker Sanofi boosted its early-stage pipeline in immunology on Thursday by signing a deal with Ablynx that could earn the Belgian biotech firm as much as 2.4 billion euros ($2.8 billion).

Jul 20 2017

Ablynx signs Sanofi deal potentially worth up to $2.8 bln

July 20 French drugmaker Sanofi boosted its early-stage pipeline in immunology on Thursday by signing a deal with Ablynx that could earn the Belgian biotech firm as much as 2.4 billion euros ($2.8 billion).

Jul 20 2017

BRIEF-Ablynx achieves second milestone in immuno-oncology collaboration

* ABLYNX ACHIEVES SECOND MILESTONE IN IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO. , INC., KENILWORTH, NEW JERSEY, USA

Jun 27 2017

BRIEF-Ablynx initiates study of caplacizumab in healthy Japanese subjects

* ABLYNX INITIATES A SINGLE AND MULTIPLE DOSE PHASE I STUDY OF CAPLACIZUMAB IN HEALTHY JAPANESE SUBJECTS

Jun 26 2017

BRIEF-Ablynx to receive 15 million euros milestone payment

* NOVEL NANOBODY TO START CLINICAL DEVELOPMENT IN OSTEOARTHRITIS - ABLYNX TO RECEIVE €15 MILLION MILESTONE PAYMENT

May 22 2017

BRIEF-Ablynx Q1 revenues eur 9.1 million (2016 eur 27.4 million)

* Q1 OPERATING LOSS OF EUR 20.2 MILLION (2016: LOSS EUR 0.7 MILLION)

May 11 2017

BRIEF-Ablynx completes patient recruitment in its Phase III HERCULES study of caplacizumab for the treatment of aTTP

* Ablynx completes patient recruitment in its Phase III HERCULES study of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)

May 02 2017

Earnings vs. Estimates